Back to results
US 10,420,764 B2Granted
Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
AssigneeAstraZeneca AB
InventorsNoel Alan Weldon Baker, Alpesh Mistry
Life of this patent
Estimating the term…
Abstract
There are provided pharmaceutical compositions comprising a compound of Formula (I) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Claims4
A pharmaceutical composition comprising 15% w/w to 25% w/w of the compound of Formula (I):
- and 15% w/w to 25% w/w of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution at a pH where the compound of Formula (I) is no more than slightly soluble, wherein the effervescent agent is magnesium carbonate;
- wherein the composition comprises between 0.25% w/w and 8% w/w of an alternative lubricant;
- wherein the alternative lubricant is glyceryl dibehenate;
- and further comprising one or more pharmaceutically acceptable ingredients.
1 more element
A pharmaceutical composition comprising:
- (a) 15% w/w to 25% w/w of a pharmaceutically active compound, wherein the pharmaceutically active compound consists of the compound of Formula (I):
- and
- (b) 15% w/w to 25% w/w of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution, wherein the effervescent agent is magnesium carbonate;
- wherein the composition comprises between 0.25% w/w and 8% w/w of an alternative lubricant;
- wherein the alternative lubricant is glyceryl dibehenate;
- and
- (c) further comprising one or more pharmaceutically acceptable ingredients.
4 more elements
Dependencies are inferred from the claim text.